Efficacy and safety of fixed ‐dose comBination therApy with gemigLiptin (50 mg) and rosuvAstatiN (20 mg) Compared with Each monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double‐blind, controlled, phase 3 trial

Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.

Source: Diabetes, Obesity and Metabolism - August 7, 2018 Category: Endocrinology Authors: Ji Cheol Bae , Kyung Wan Min , Yong Hyun Kim , Kyoung ‐Ah Kim , Eun‐Gyoung Hong , Cheol‐Young Park , Song Han , Bong‐Soo Cha Source Type: research